BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+32.57%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.65B
AUM Growth
+$9.65B
(+23%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
1.49%
Top 10 Holdings %
Top 10 Hldgs %
77.89%
Holding
100
New
5
Increased
16
Reduced
3
Closed
6
Top Buys
| 1 |
Insmed
INSM
|
$61.3M |
| 2 |
CRISPR Therapeutics
CRSP
|
$34.9M |
| 3 |
Summit Therapeutics
SMMT
|
$26.3M |
| 4 |
Immunovant
IMVT
|
$21.7M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$21.2M |
Top Sells
Sector Composition
| 1 | Healthcare | 98.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sera Prognostics
SERA
$129M
| $42.4M | 0.44% |
5,434,399
| – | – |
|
|
27
CRISPR Therapeutics
CRSP
$4.82B
| $39.6M | 0.41% |
843,075
+743,075
| +743% | +$34.9M |
|
28
Xenon Pharmaceuticals
XENE
$2.99B
| $39.1M | 0.41% |
993,679
| – | – |
|
|
29
Immunovant
IMVT
$2.91B
| $34.9M | 0.36% |
1,225,410
+760,692
| +164% | +$21.7M |
|
30
Cerus
CERS
$251M
| $33.9M | 0.35% |
19,477,339
| – | – |
|
31
IDEAYA Biosciences
IDYA
$2.26B
| $33.6M | 0.35% |
1,062,123
| – | – |
|
32
Roivant Sciences
ROIV
$8.6B
| $32.3M | 0.33% |
2,798,716
| – | – |
|
33
Akero Therapeutics
AKRO
$3.65B
| $31.5M | 0.33% |
1,097,082
| – | – |
|
34
Krystal Biotech
KRYS
$4.35B
| $30.9M | 0.32% |
169,934
| – | – |
|
35
Celcuity
CELC
$2.3B
| $28M | 0.29% |
1,874,978
| – | – |
|
36
Monte Rosa Therapeutics
GLUE
$309M
| $26.1M | 0.27% |
4,916,095
| – | – |
|
37
Dyne Therapeutics
DYN
$1.92B
| $24.1M | 0.25% |
672,096
| – | – |
|
38
Biomea Fusion
BMEA
$114M
| $21.3M | 0.22% |
2,108,949
| – | – |
|
|
BCAX
39
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $21.2M | 0.22% |
+833,333
| New | +$21.2M |
|
40
Prelude Therapeutics
PRLD
$69.1M
| $21M | 0.22% |
10,123,824
| – | – |
|
|
CNTA
41
Centessa Pharmaceuticals
CNTA
$2.13B
| $19.6M | 0.2% |
1,227,178
+677,966
| +123% | +$10.8M |
|
42
Neurogene
NGNE
$284M
| $19.1M | 0.2% |
456,015
| – | – |
|
43
Praxis Precision Medicines
PRAX
$980M
| $18.6M | 0.19% |
323,105
+191,572
| +146% | +$11M |
|
|
ALMS
44
Alumis Inc. Common Stock
ALMS
$483M
| $16.7M | 0.17% |
1,562,500
| – | – |
|
45
Merus
MRUS
$5.04B
| $15M | 0.16% |
300,000
| – | – |
|
46
TScan Therapeutics
TCRX
$106M
| $13.9M | 0.14% |
2,784,792
| – | – |
|
47
Neumora Therapeutics
NMRA
$283M
| $13.7M | 0.14% |
1,034,600
| – | – |
|
48
Xencor
XNCR
$594M
| $13.5M | 0.14% |
670,431
+125,000
| +23% | +$2.51M |
|
|
TSVT
49
DELISTED
2seventy bio
TSVT
| $11.8M | 0.12% |
2,497,526
| – | – |
|
50
Fate Therapeutics
FATE
$115M
| $10.5M | 0.11% |
2,997,772
| – | – |
|